Investigational drug · Phase 2
LASN01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "LASN01"
First trial start
2022
Jun 6, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LASN01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease
- Pulmonary Fibrosis
- Graves Ophthalmopathy
- Graves Orbitopathy
- Thyroid Associated Ophthalmopathy
- Endocrine System Diseases
- Orbital Diseases
- Proptosis
- Eye Diseases
Approved drugs for the same conditions: Respiratory · Endocrinology and women's health · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "LASN01" as an intervention, largest first.
Lassen Therapeutics 1 PTY LTDIndustry
NCT05331300 · 75 participants · Start Jun 6, 2022 · Primary completion Nov 27, 2024
Drug: LASN01; LASN01 and 2 more · For: Pulmonary Fibrosis; Thyroid Eye Disease
Sites: Hurstville, Australia; Brisbane, Australia; Melbourne, Australia · 4 sites in all
Lassen Therapeutics Inc.Industry
NCT06226545 · 41 participants · Start Mar 5, 2024 · Primary completion Apr 22, 2025
Drug: LASN01; LASN01 and 2 more · For: Thyroid Eye Disease; Graves Ophthalmopathy; Graves Orbitopathy and 5 more
Sites: Beverly Hills, California; Palo Alto, California; San Diego, California · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- IL-11 in fibrostenotic Crohn's disease: historical agonism, the selective-inhibition hypothesis, and evidence thresholds for translation.
Chen H, Liang S · Front Pharmacol 2026
- IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.
King DJ, Swaney JS, Rich C, et al. · Sci Rep 2026
- Therapeutic effect of IL-11 inhibition on the pathogenesis of thyroid eye disease.
Yoon HJ, Park HY, Kim JY, et al. · J Mol Endocrinol 2026
Also in development for Thyroid Eye Disease
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- KHN939Phase 32 trials
Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease
- linsitinibPhase 32 trials
Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- lonigutamabPhase 21 trial
ACELYRIN Inc. · Thyroid Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.